Associate Director, Market Research and Competitive Intelligence

Role Overview

The Associate Director, Market Research & Competitive Intelligence will lead primary market research and competitive intelligence to support commercialization of avexitide in post-bariatric hypoglycemia (PBH). This highly visible, hands-on role will develop and execute an integrated insights plan spanning foundational, strategic, communications, and tracking research, including HCP and patient attitudes, trial, and usage (ATU) studies.

What You Will Do

The role will also lead competitive intelligence efforts that provide timely, objective, and actionable perspectives on the PBH disease state, emerging treatment landscape, competitor activity, and market implications. While PBH and avexitide commercialization will be the primary focus, this individual will provide fit-for-purpose market research and competitive intelligence support for New Products Planning (NPP), pipeline assets, and selected business-development needs.

Why It Might Be a Fit

The ideal candidate will have 10+ years of relevant experience in pharmaceutical, biotechnology, healthcare, life sciences consulting, primary market research, competitive intelligence, commercial insights, or related discipline, with a strong background in leading qualitative and quantitative pharmaceutical market research across the project lifecycle.

Requirements

• Bachelor’s degree required in business, marketing, market research, social sciences, public health, life sciences, statistics, or a related field
• 10+ years of relevant experience in pharmaceutical, biotechnology, healthcare, life sciences consulting, primary market research, competitive intelligence, commercial insights, or related discipline
• Demonstrated experience leading qualitative and quantitative pharmaceutical market research across the project lifecycle
• Experience with strategic and tracking research, including HCP or patient ATU studies
• Experience developing or leading competitive intelligence programs
• Experience supporting launch-stage brands, specialty or rare-disease markets, and pre-commercial assets